Role of post-therapy 99mTc-MIBI single-photon emission computed tomography/computed tomography scan in predicting survival in patients with high-grade glioma.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Jun 2021
01 Jun 2021
Historique:
pubmed:
25
2
2021
medline:
12
11
2021
entrez:
24
2
2021
Statut:
ppublish
Résumé
High-grade gliomas (HGGs) carry dismal prognosis with survival typically reported as less than a year. We explored the predictive value of qualitative and quantitative evaluations of post-treatment 99m-technetium-labelled methoxyisobutylisonitrile (99mmTc-MIBI) brain single-photon emission computed tomography-computed tomography (SPECT/CT) tumor uptake in relation to overall survival (OS) in patients with HGG. Thirty patients with pathologically or radiologically documented high-grade glioma (HGG) were prospectively recruited for this study (24 male, 6 female; mean age 43 ± 14 years). All patients had a clinical or radiological suspicion of residual/recurrent tumor after initial therapy. 99mTc-MIBI brain SPECT/CT scanning was performed, and the scans were evaluated qualitatively on a five-point probability score (1-5, scores ≥3 considered positive for residual/recurrent tumor); and quantitively via drawing volumes of interest (VOI) on the suspected lesions and normal contralateral brain tissue. All patients were followed up for 1 year or till death. Positive visual MIBI results were associated with poor survival. Among 10 patients with negative MIBI scores, only two patients died (OS = 75%), while 11/20 patients reported positive on MIBI died, with a median survival of 9 months (OS = 14.5%; P = 0.03). All patients with active isocontour volume ≤1.96 cm3 were alive at the end of the study, compared to a median survival of 9 months and OS of 12% for patients with an isocontour volume of >1.97% (P = 0.003). In patients with HGG, post-therapy brain SPECT/CT with 99mTc-MIBI can provide useful prognostic information.
Identifiants
pubmed: 33625186
doi: 10.1097/MNM.0000000000001385
pii: 00006231-202106000-00006
doi:
Substances chimiques
Technetium Tc 99m Sestamibi
971Z4W1S09
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
625-632Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012; 14 (Suppl 5):v1–49.
Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, et al. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017; 15:1331–1345.
de Jong MC. Predicting radioresistance in head and neck cancer. 2017. http://www.moniquedejong-research.eu/phd/wp-content/uploads/2017/12/2017_Predicting-radioresistance-in-head-and-neck-cancer_PhD-thesis_Monique-C-de-Jong_V2.pdf . [Accessed 24 October 2020]
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001; 95:190–198.
Shinojima N, Kochi M, Hamada J, Nakamura H, Yano S, Makino K, et al. The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg. 2004; 101:219–226.
Liu Y, Shete S, Etzel CJ, Scheurer M, Alexiou G, Armstrong G, et al. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol. 2010; 28:2467–2474.
Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455:1061.
Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008; 9:453–461.
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28:1963–1972.
Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007; 48:1468–1481.
Bucerius J, Ahmadzadehfar H, Biersack HJ. 99mTc-sestamibi: clinical applications. Berlin, New York: Springer; 2012.
Cheng X, Li Y, Xu Z, Li D, Wang J. A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin Neurosci. 2011; 18:307–312.
Filippi L, Schillaci O, Santoni R, Manni C, Danieli R, Simonetti G. Usefulness of SPECT/CT with a hybrid camera for the functional anatomical mapping of primary brain tumors by [Tc99m] tetrofosmin. Cancer Biother Radiopharm. 2006; 21:41–48.
Brunt EM. Pathology of fatty liver disease. Mod Pathol. 2007; 20 (Suppl 1):S40–S48.
Gupta A, Sharma P, Patel CD, Maharjan S, Pandey A, Kumar R, et al. Size-dependent thresholding as an optimal method for tumor volume delineation on positron emission tomography-computed tomography: a Phantom study. Indian J Nucl Med. 2011; 26:22.
Youden WJ. Index for rating diagnostic tests. Cancer. 1950; 3:32–35.
Lesniak MS. Gene therapy for malignant glioma. Expert Rev Neurother. 2006; 6:479–488.
Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993; 71:2585–2597.
Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, et al.; Glioma Outcomes Investigators. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003; 99:467–473.
Alexiou GA, Tsiouris S, Kyritsis AP, Fotakopoulos G, Goussia A, Voulgaris S, Fotopoulos AD. The value of 99mTc-tetrofosmin brain SPECT in predicting survival in patients with glioblastoma multiforme. J Nucl Med. 2010; 51:1923–1926.
Beauchesne P, Pedeux R, Boniol M, Soler C. 99mTc-sestamibi brain SPECT after chemoradiotherapy is prognostic of survival in patients with high-grade glioma. J Nucl Med. 2004; 45:409–413.
Soler C, Beauchesne P, Maatougui K, Schmitt T, Barral FG, Michel D, et al. Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. Eur J Nucl Med. 1998; 25:1649–1657.
Deltuva VP, Jurkienė N, Kulakienė I, Bunevičius A, Matukevičius A, Tamašauskas A. Introduction of novel semiquantitative evaluation of (99m)Tc-MIBI SPECT before and after treatment of glioma. Medicina (Kaunas). 2012; 48:15–21.
Deltuva V, Bunevicius A, Jurkiene N, Kulakiene I, Tamasauskas A. Perioperative single photon emission computed tomography in predicting survival of malignant glioma patients. Oncol Lett. 2012; 4:739–744.
Zolotova SV, Khokhlova EV, Belyashova AS, Nikolaeva AA, Starovoytov DV, Igoshina EN, et al. Investigation of the metabolic features of primary glioblastomas by Tc-MIBI SPECT/CT and evaluation of their effect on disease prognosis. Burdenko J Neurosurg. 2019; 83:17–26.
Le Jeune N, Perek N, Denoyer D, Dubois F. Study of monoglutathionyl conjugates TC-99M-sestamibi and TC-99M-tetrofosmin transport mediated by the multidrug resistance-associated protein isoform 1 in glioma cells. Cancer Biother Radiopharm. 2005; 20:249–259.
Moretti JL, Hauet N, Caglar M, Rebillard O, Burak Z. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur J Nucl Med Mol Imaging. 2005; 32:836–842.
Piwnica-Worms D, Holman BL. Noncardiac applications of hexakis(alkylisonitrile) technetium-99m complexes. J Nucl Med. 1990; 31:1166–1167.
Urbano N, Scimeca M, Tancredi V, Bonanno E, Schillaci O. 99mTC-sestamibi breast imaging: current status, new ideas and future perspectives. Semin Cancer Biol. 2020. doi: 10.1016/j.semcancer.2020.01.007
doi: 10.1016/j.semcancer.2020.01.007
Ak I, Gulbas Z, Altinel F, Vardareli E. Tc-99m MIBI uptake and its relation to the proliferative potential of brain tumors. Clin Nucl Med. 2003; 28:29–33.
Alexiou GA, Tsiouris S, Vartholomatos G, Fotakopoulos G, Papadopoulos A, Kyritsis AP, et al. Correlation of glioma proliferation assessed by flow cytometry with (99m)Tc-Tetrofosmin SPECT uptake. Clin Neurol Neurosurg. 2009; 111:808–811.
Nagamachi S, Jinnouchi S, Nabeshima K, Nishii R, Flores L 2nd, Kodama T, et al. The correlation between 99mTc-MIBI uptake and MIB-1 as a nuclear proliferation marker in glioma – a comparative study with 201Tl. Neuroradiology. 2001; 43:1023–1030.
Du Y, Tsui BM, Frey EC. Partial volume effect compensation for quantitative brain SPECT imaging. IEEE Trans Med Imaging. 2005; 24:969–976.